2022 Will Bring New Questions For Sarepta; Jefferies Raises Price Target From $7 To $50

By: via Benzinga
Jefferies raised its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) as the din dies down on the euphoria generated by the company ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.